摘要
Objective: To study the feasibility to use vascular endothelial growth factor (VEGF) gene therapy for salivary glands, and observe the saliva content of VEGF. Methods: VEGF cDNA was cloned into eukaryotic expression vector pBKCMV, and VEGF gene was transferred into rat maxillary glands mediated by lipofectin AMINE. The expression of VEGF gene was observed with RT-PCR, and the saliva content of VEGF was determined with ELISA. Results: The expression of VEGF gene and the saliva content of VEGF were significantly higher in the experimental group than in the control groups. The 2 parameters reached the peak 2-3 d after treatment and mintained the high level for 5 d. Conclusion: One findings show that VEGF can express stably and persistently in salivary glands. Meanwhile, the saliva content of VEGF is increased, which suggest that VEGF gene therapy might be a new method to promote the healing of oral mucosal ulcers.
Objective: To study the feasibility to use vascular endothelial growth factor (VEGF) gene therapy for salivary glands, and observe the saliva content of VEGF. Methods: VEGF cDNA was cloned into eukaryotic expression vector pBKCMV, and VEGF gene was transferred into rat maxillary glands mediated by lipofectin AMINE. The expression of VEGF gene was observed with RT-PCR, and the saliva content of VEGF was determined with ELISA. Results: The expression of VEGF gene and the saliva content of VEGF were significantly higher in the experimental group than in the control groups. The 2 parameters reached the peak 2-3 d after treatment and mintained the high level for 5 d. Conclusion: One findings show that VEGF can express stably and persistently in salivary glands. Meanwhile, the saliva content of VEGF is increased, which suggest that VEGF gene therapy might be a new method to promote the healing of oral mucosal ulcers.
